Cancer therapy products are leading the pack in professional health journal advertising through May 2014

Top 5 Drug Classes Through May 2014

Print advertising dollars in professional health journals reached more than $251 million through May 2014, a 4% increase year-over-year, according to Kantar Media. The leading product class continues to be Cancer Therapy Products with more than $17 million spent in advertising in print medical journals. This product class makes up 7% of the total market share through May.

The top product classes by dollars are as follows:

Top 5 Print Ad Drug Classes (Dollars): May 2014

  1. Cancer Therapy Products - $18 MM (-7%)
  2. Diabetes Oral - $10 MM (+127%)
  3. Anticoagulants Oral - $9 MM (-32%)
  4. Antidepressants - $6 MM (N/A)
  5. SSRI/SNRI - $5 MM (+209%)

The percentage changes compare May 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.

Search article